Welcome to our dedicated page for Else Nutrition H news (Ticker: BABYF), a resource for investors and traders seeking the latest updates and insights on Else Nutrition H stock.
Else Nutrition Holdings Inc operates in the plant-based nutrition sector, developing alternatives to traditional infant and toddler formulas. The company's news coverage reflects developments in product launches, retail expansion, regulatory matters, and operational updates relevant to the plant-based nutrition market.
News related to Else Nutrition typically includes product development announcements, retail partnership updates, and regulatory developments affecting the infant nutrition industry. The company's operations intersect with evolving food regulations, plant-based industry trends, and consumer nutrition preferences. Investors tracking this stock can expect coverage of manufacturing milestones, distribution agreements, and market expansion initiatives.
The plant-based nutrition sector generates news around regulatory changes, consumer trends, and competitive developments. Else Nutrition's coverage includes updates on retail availability, operational achievements, and financial reporting. The company's focus on infant and toddler nutrition means news often relates to regulatory compliance, product safety standards, and nutritional research developments.
This news feed aggregates announcements from the company alongside third-party coverage of the plant-based nutrition industry. Investors interested in specialty food manufacturing, plant-based consumer products, and alternative nutrition markets can follow developments affecting Else Nutrition's business operations and market position.
Else Nutrition (OTC: BABYF) reported that 2025 was a transformational year, including company-wide cost and headcount reductions, supply-chain and manufacturing efficiency improvements, and focused marketing investments to prioritize toddler and baby cereal categories. The company said temporary production funding shortfalls in 2025 caused supply constraints and revenue losses, and expects more stable inventory and revenue growth in 2026 with improved funding and lower operating costs. In November 2025, a U.S. congressional directive and FDA funding package was signed to streamline approval pathways for non-dairy, non-soy plant-based infant formulas, which Else says improves its regulatory outlook. Else expects to pursue manufacturing efficiencies and aims for cash-flow breakeven between late 2026 and early 2027.
Else Nutrition (TSX: BABY / OTC: BABYF) announced that its 2025 annual general meeting of shareholders will be held on December 29, 2025. The company said a notice, management information circular, and form of proxy were mailed to shareholders of record as of November 10, 2025.
The company also confirmed it received TSX approval to extend the date to hold the annual general meeting.
Else Nutrition (OTC: BABYF) on Nov 18, 2025 said the Fiscal Year 2026 U.S. federal budget signed by President Trump includes Congressional report language (H. Rept. 119-172) that directs the FDA to streamline regulatory pathways and issue formal guidance for plant-based, non-soy, non-dairy infant formulas.
The company says the provision—linked to Operation Stork Speed—was advanced through its government affairs efforts and that FDA guidance work may begin as federal employees return following the government shutdown. Else states it is positioned to accelerate regulator engagement and pursue U.S. infant-formula market access once guidance is implemented.
Else Nutrition (OTC:BABYF) reported Q3 2025 results for the quarter ended Sept 30, 2025, showing a pronounced operational turnaround. Gross profit margin expanded to 34% (versus -9% in Q3 2024). Operating expenses fell 68% to $1.15M, and operating loss narrowed to $0.58M from $3.72M a year earlier. revenue was $1.66M (down from $1.79M) amid temporary out-of-stock issues. Cash at quarter-end was $91K and trade payables declined 46% to $1.53M. Management hosted a conference call Nov 17, 2025 and cited ongoing regulatory, clinical and partnership work to support future commercialization.
Else Nutrition (OTC: BABYF) rescheduled its 2025 third quarter business update conference call to 10:00 AM Eastern on Monday, November 17, 2025.
The company will discuss Q3 2025 financial results (period ended September 30, 2025), corporate progress, and other developments. Live participation is available by telephone (toll free U.S. 1-877-407-9219; international +1-412-652-1274) or via webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=5ZSyvIjp and the Investor Relations site https://investors.elsenutrition.com/.
A webcast replay will be available on the Investor Relations site through November 17, 2026. A telephone replay will be available ~3 hours after the call through December 1, 2025 (U.S. 1-877-660-6853; international +1-201-612-7415; conference ID: 13757060).
Else Nutrition (OTC: BABYF) will host a business update conference call on Tuesday, November 18, 2025 at 10:00 AM ET to discuss third quarter 2025 financial results (period ended September 30, 2025), corporate progress and other developments.
Investors can join by telephone (toll free U.S. 1-877-407-9219; international +1-412-652-1274) or via webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=5ZSyvIjp and the Investor Relations site. A webcast replay will be available on the Investor Relations site through November 18, 2026. A telephone replay will be available about three hours after the call through December 2, 2025 (U.S. 1-877-660-6853; international +1-201-612-7415) using conference ID 13757060.
ELSE NUTRITION (OTCQX:BABYF / TSX:BABY) approved a 1-for-10 share consolidation effective at market open on November 6, 2025. The consolidation will reduce issued and outstanding common shares from 374,114,284 pre-consolidation to approximately 37,411,430 post-consolidation, subject to rounding.
Proportionate adjustments will apply to outstanding stock options, warrants, and other convertibles. New CUSIP 290257500 and ISIN CA2902575000 will apply. Fractional shares will be rounded down if <0.5 and rounded up if ≥0.5. Registered shareholders in certificated form will receive a letter of transmittal from Computershare; DRS holders will receive automatic post-consolidation DRS statements. Non-registered holders should consult their intermediaries. Warrant holders will be notified under the applicable warrant indentures.
Else Nutrition (BABYF) reported its Q2 2025 financial results, showing significant operational challenges but strategic progress. Revenue declined to CAD $1.5 million from CAD $2.6 million in Q2 2024, while gross profit turned negative at -CAD $0.06 million with a -3.7% margin.
The company achieved notable cost reductions, with operating expenses decreasing by 62% to CAD $1.3 million year-over-year. Despite temporary inventory constraints affecting Q2 performance, management highlighted regulatory progress in the US market and ongoing European production transition. The company maintains a cash balance of CAD $0.9 million and targets cash-flow positivity by late 2026 or early 2027.
Else Nutrition Holdings (BABYF) has scheduled a business update conference call for September 16, 2025, at 10:00 a.m. Eastern Time. The call will discuss the company's Q2 2025 financial results and corporate developments.
Investors can access the call via telephone (toll-free 1-877-407-9219 for U.S. callers or +1-412-652-1274 for international callers) or through a webcast. A replay will be available on the company's investor relations website through September 16, 2026, and via telephone through September 30, 2025.
Else Nutrition (OTCQX: BABYF) reported its Q1 2025 financial results, maintaining revenue at $2.1 million year-over-year while significantly improving operational efficiency. The company achieved a notable reduction in operating expenses by 48% to $2.2 million and increased gross profit margin to 25% from 8% in Q1 2024.
Key strategic initiatives include shifting powder formula manufacturing to Europe to reduce production costs and improve margins. The company is also optimizing its retail distribution model and pursuing regulatory advancement through Operation Stork Speed and the FY2026 Agriculture Appropriations Bill, which could streamline FDA approval pathways for plant-based infant nutrition alternatives.
The company ended Q1 2025 with a cash balance of $0.2 million, including restricted cash, and is exploring strategic collaborations to accelerate growth.
FAQ
What is the current stock price of Else Nutrition H (BABYF)?
What is the market cap of Else Nutrition H (BABYF)?
